Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases

Monoclonal antibodies (mAbs) are antibodies of a single antigen specificity produced by identical immune cells, i.e., clones of a common germ cell. They offer unprecedented opportunities to drug development because of their ability to target almost any cell surface or secreted molecule with remarkable efficacy and safety. In this chapter, the application of human mAbs in the treatment of inflammatory diseases is reviewed. We discuss in detail several mAb-based drugs such as anti-tumor necrosis factor (anti-TNF), anti-interleukin-1 (anti-IL-1) receptor, anti-IL-6 receptor, anti-α4 integrin subunit, and anti-CD20 agents, all of which have been documented by clinical trials to be efficacious and have been approved for the therapy of several inflammatory and immune diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, spondyloarthropathies, juvenile arthritis, psoriasis, psoriatic arthritis, and others. These novel drugs can be used either as a monotherapy or in combination with other conventional therapeutic modalities, particularly if the disease under treatment is refractory to therapy using solely conventional techniques. As a large variety of mAb-based agents targeting a plethora of cytokines, chemokines, adhesion and co-stimulatory molecules, receptors, as well as diverse cell types, are presently under investigation, the therapeutic armamentarium of the clinician is expected to greatly broaden in the near future, providing improved pati...
Source: Springer protocols feed by Immunology - Category: Allergy & Immunology Source Type: news

Related Links:

Mesenchymal stem cells (MSCs) possess anti-inflammatory properties and tissue differentiation potential. We prepared a rat shoulder arthritis model by injecting monoiodoacetate (MIA) into the shoulder and investigated the intraarticular administration of MSCs from the aspects of the cartilage protective effect associated with the cell ’s anti-inflammatory activity and inhibition of the central sensitization of pain. When MIA was administered in this model, anti-calcitonin gene related peptide (CGRP) was expressed in the shoulder joint and C5 spinal dorsal horn.
Source: Journal of Shoulder and Elbow Surgery - Category: Orthopaedics Authors: Source Type: research
Total elbow arthroplasty (TEA) is commonly performed in patients with rheumatoid arthritis (RA). The purpose of this study was to compare outcomes and complications of unlinked and linked TEA using a convertible system in patients with RA.
Source: Journal of Shoulder and Elbow Surgery - Category: Orthopaedics Authors: Tags: Elbow Source Type: research
Publication date: Available online 17 October 2019Source: Pharmacological ResearchAuthor(s): Shing T. Law, Peter C. TaylorAbstractAdvances in understanding of the pathophysiology of rheumatoid arthritis with concurrent advances in protein engineering led to the development of biological disease-modifying antirheumatic drugs which have dramatically revolutionized the treatment of this condition. This review article focuses on the role of biological agents currently employed in the treatment of rheumatoid arthritis, as well as novel biological agents in development.Graphical abstract
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
TIME held its first TIME 100 Health Summit on Thursday aiming to define — and shape — the future of health care. The Summit, which is an offshoot of the magazine’s annual TIME 100 list of influential people, featured scientists, politicians and entertainers, such as former President Bill Clinton, former Vice President Al Gore, NIH Director Dr. Francis Collins, actress Selma Blair, NBA commissioner Adam Silver, comedian Tig Notaro and former Planned Parenthood President Dr. Leana Wen. The day included a range of interviews, panels and performances. Here are the biggest moments from the Summit. Former Vice ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Comedy HealthSummit19 onetime Source Type: news
ConclusionThe definite diagnosis was not defined via vigorous myopathic and rheumatologic investigations. Detailed clinical examination and skeletal survey, followed by genotypic confirmation, were our fundamental pointers to rule out the false diagnosis of juvenile rheumatoid arthritis and rheumatoid polyarthritis in the adult group of patients. We wish to stress that the clinical/radiological phenotype is the baseline tool to establish a definite diagnosis and to guide the geneticist toward proper genotype.Key Points•Joint pain and difficulties in walking/climbing the stairs are characteristic features encountered i...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
AbstractPediatric Crohn ’s disease (CD) is characterized by an aggressive course that commonly requires more intensive pharmacological and surgical treatments. In spite of the therapeutic advances in monitoring and management, including the widespread use of biologic therapy, the cumulative incidence of surgery in childr en with CD is still high. However, surgery is usually not curative and disease recurrence after small bowel resection is common. Gastrointestinal endoscopy is currently the gold standard to evaluate disease progression after surgery, but other non-invasive methods have been suggested. Although the e ...
Source: Pediatric Drugs - Category: Pediatrics Source Type: research
ConclusionsThis real-world study of commercially insured patients with RA suggests that opioid use among these  patients is prevalent. There was a small decrease in overall opioid utilization after TNFi initiation.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
This study is the first to assess this technique in a large number of people with knee osteoarthritis. It was found to distinguish between healthy knees and those afflicted by  this  "wear-and-tear" form of arthritis.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Changes announced at the beginning of October have now been delayed for Actemra, Benlysta, Cimzia, Orencia and Simponi Aria, but changes to the Stelara policy remain in effect.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Drug Updates Practice Management Arthritis prior authorization UnitedHealthCare (UHC) Source Type: research
Clinical / Medical
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
More News: Allergy & Immunology | Arthritis | Clinical Trials | Crohn's Disease | Germ Cell Tumors | Inflammatory Bowel Disease | Psoriasis | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Ulcerative Colitis